Bone and joint health markers in persons with hemophilia A (PwHA) treated with emicizumab in the HAVEN 3 clinical trial

Anna Kiialainen,1 Markus Niggli,1 Christine Kempton,2 Giancarlo Castaman,3 Tiffany Chang,4 Ido Paz-Priel,4 Joanne I. Adamkewicz4

Summary

Hemophilia A (HA) can impact bone and joint health.1 Treatment of HA with emicizumab was shown to be efficacious and well tolerated in the HAVEN clinical trials.1,4 The effect of emicizumab on bone and joint health was assessed in the HAVEN 3 clinical trial.

Treatment with emicizumab led to clinically relevant improvements in joint function in those with target joint disease (i.e., with a joint bleed). Bone and joint biomarkers remained within the normal range during emicizumab prophylaxis.

PeHA had better joint health if they had previously taken preventive replacement FVIII rather than on-demand FVIII.

Over a hundred PeHA from HAVEN 3 supplied joint function and biomarker data, through data cut-off: October 4, 2018 (Figure 2).

Figure 2. PeHA who supplied HJHS and biomarker data formed the analysis population.

Both HJHS and biomarkers

Biomarkers were evaluated relating to two analysis endpoints: HAVEN joint health score (HJHS) and biomarkers. Both PeHA and persons with hemophilia A.

Characteristics of HAVEN 3 participants with evaluable HJHS and biomarker measurements (Table 1).

- At the time of this analysis (October 4, 2018), the participants in HAVEN 3 had been followed for a median of 87.4 weeks.
- The average change in joint-specific and total HJHS after 48 weeks of emicizumab prophylaxis was 3.13 and -0.25, respectively, for PeHA with at least one target joint. Around half this level of improvement was seen for PeHA without target joints.

No significant changes in bone and joint biomarkers were observed during the HAVEN 3 trial (Figure 5).

Conclusions

Clinically relevant improvements in joint function were seen in persons with hemophilia A with target joints treated with emicizumab.

Bone and joint biomarkers remained within normal ranges during the follow-up period.

Further research is required to understand the long-term effect of emicizumab prophylaxis on bone and joint health.

References


Acknowledgments

The authors would like to thank the study participants and their families, as well as the study investigators and site personnel. This study was co-sponsored/supported by Roche. Roche had no role in study design, data collection, data analysis, data interpretation, or writing the report. Please refer to the full article for additional information about the study design and funding sources.